Mycophenolate Use During Lactation

Safety Concerns in Lactation

The European League Against Rheumatism (EULAR) recommends that mycophenolate be avoided in lactating women due to insufficient safety data, and alternative immunosuppressive medications should be considered 1, 2, 3
The recommendation to avoid mycophenolate during lactation is based on insufficient data rather than documented evidence of infant harm 1

The American Gastroenterological Association and EULAR suggest that several immunosuppressive medications are considered safe alternatives during breastfeeding, including corticosteroids, azathioprine, cyclosporine, tacrolimus, and TNF inhibitors 1, 3, 4
Tacrolimus transfers into breast milk in very small amounts, between 0.06% and 0.5% of the mother's weight-adjusted dose 4
Breastfed infants of mothers on cyclosporine with whole-blood trough levels of 55-130 ng/mL had undetectable cyclosporine levels 4

Mycophenolate is extensively converted to mycophenolic acid glucuronide, which is primarily cleared through renal excretion 5, 6
For male patients, mycophenolate treatment has not demonstrated clinically relevant impact on offspring outcomes and can be continued when trying to conceive 1, 2

First-line options for immunosuppression during lactation include corticosteroids, azathioprine, tacrolimus, cyclosporine, or TNF inhibitors, according to EULAR 1, 4
Mycophenolate, cyclophosphamide, leflunomide, and JAK inhibitors should be avoided during lactation, as recommended by EULAR 1, 2

If mycophenolate is used during lactation, the infant should be monitored for potential adverse effects, including hematologic abnormalities and signs of infection 5, 6

The safety profile of mycophenolate in male patients should not be confused with its contraindication in lactating women, as stated by EULAR 1, 2
Not all immunosuppressants carry equal risk during lactation, and several alternatives have established safety profiles, according to EULAR and the American Gastroenterological Association 1, 4